Nuclera: Funding, Investors & Team (Sep 2026)
At Nuclera, our mission is to better human health by making proteins accessible. We believe that providing rapid access to high-quality, soluble, active proteins at the benchtop will allow researchers to accelerate their protein projects. Fail fast, succeed faster. Our eProtein Discovery™ system automates construct screening for the best soluble expression and purification yields of different proteins in under 24 hours. From there, protein scale-up happens the next day (up to the mg scale) right on the benchtop - delivering reliable protein in-hand in less than 48 hours. Nuclera’s technology integrates cell-free protein synthesis and digital microfluidics on smart cartridges, allowing rapid progress on protein projects through a benchtop, automated, high-throughput protein access system. Founded in 2013 by PhD students at the University of Cambridge, the company now has a presence in Cambridge, UK and Boston, MA employing over 100 employees.
Nuclera has raised $104M across 4 funding rounds on record, the most recent a Series C of $12.0M announced in Jan 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Nuclera Company Profile and Key Stats
Latest funding round on record: Jan 2026.
Nuclera Funding Rounds
Nuclera raised $15.5M in a Series B announced in Jul 2022.
1.9 years later, an undisclosed round of $1.5M was announced in Jun 2024.
4 months later, a Series C of $75.0M was announced in Oct 2024.
1.3 years later, a Series C of $12.0M was announced in Jan 2026.
Nuclera Founders and Leadership Team
No contact details are on record for this team yet.
Nuclera Funding Compared to Other Biotechnology Startups
Nuclera's latest round of $12.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Nuclera in Biotechnology and Cambridge
Companies Similar to Nuclera
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…
Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…
Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps…
Five is a biometric payment services company that offers thumb recognition technology for safe transactions.
Nuclera Funding FAQs
What does Nuclera do?
At Nuclera, our mission is to better human health by making proteins accessible. We believe that providing rapid access to high-quality, soluble, active proteins at the benchtop will allow researchers to accelerate their protein projects. Fail fast, succeed faster. Our eProtein Discovery™ system automates construct screening for the best soluble expression and purification yields of different proteins in under 24 hours. From there, protein scale-up happens the next day (up to the mg scale) right on the benchtop - delivering reliable protein in-hand in less than 48 hours. Nuclera’s technology integrates cell-free protein synthesis and digital microfluidics on smart cartridges, allowing rapid progress on protein projects through a benchtop, automated, high-throughput protein access system. Founded in 2013 by PhD students at the University of Cambridge, the company now has a presence in Cambridge, UK and Boston, MA employing over 100 employees.
How much funding has Nuclera raised?
Nuclera has raised $104M across 4 rounds on record. The most recent is a Series C of $12.0M announced in Jan 2026.
When did Nuclera last raise funding?
Nuclera's most recent funding round on record is a Series C of $12.0M, announced in Jan 2026.
Who founded Nuclera?
FundedIQ lists Gordon Mcinroy (Founder), Jiahao Huang (Founder) at Nuclera.
Who is the CEO of Nuclera?
Michael Chen is listed as CEO at Nuclera.
Where is Nuclera headquartered?
Nuclera is based in Cambridge, Cambridgeshire, United Kingdom.
How many employees does Nuclera have?
Nuclera is in the 101-250 employee band.
How does Nuclera's funding compare to other Biotechnology startups?
Nuclera's latest round of $12.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Nuclera Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Nuclera is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.